|
Due to high demand for space on the important Idiopathic Pulmonary Fibrosis (IPF) conference call coming up on Tuesday regarding the data on three important IPF trials, we have a new larger capacity number that can handle the volume of participants. Please make note of the NEW number for the call on Tuesday, May 27th, 11 a.m. Eastern.
The NEW number is: Toll-Free 1-(855) 210-9373. For international callers, the number is 817-382-4419.
Join an Important Coalition for Pulmonary Fibrosis Conference Call
Tuesday May 27, 11 A.M. Eastern
Learn About Data on Three Important Drug Trial Outcomes from
Expert Andy Tager, M.D.
Dr. Tager will discuss data from from the InterMune, Boehringer Ingelheim and NIH Trials. Mary Tagliaferri, MD from InterMune, Inc. will also be on the call to answer questions regarding the Expanded Access Program for pirfenidone.
Over the last several days, medical experts including researchers and physicians have been discussing the positive data reported by two drug trials in idiopathic pulmonary fibrosis (IPF) and negative results of a third, and discussing the long term meaning of the data at the American Thoracic Society (ATS) meeting in San Diego. On Tuesday, patients will have an opportunity to learn about the data and ask their own questions.
The Coalition for Pulmonary Fibrosis (CPF) is hosting a conference call for patients and families affected by IPF. Andrew Tager, M.D., an expert in IPF from Massachusetts General Hospital in Boston, MA, will be discussing the data reported on all three trials at the ATS conference.
The CPF represents thousands of patients suffering from the disease in the US that claims as many lives each year as breast cancer yet has limited awareness and recognition.
Who should join the call? Pulmonary Fibrosis Patients, Family Members and Caregivers
What are the trials? Boehringer Ingelheim’s Nintedanib, InterMune’s Pirfenidone and the National Institutes of Health’s PANTHER trial of N-acetylcysteine (NAC)
How to call in? Dial in number: NOTE THESE ARE NEW, UPDATED NUMBERS: Toll-Free 1-(855) 210-9373. For international callers, the number is 817-382-4419. You may be asked for the Conference ID and it is: 52075135. The replay of the call will be available until July 27, 2014.
When? Tuesday, May 27, 11 a.m. Eastern, 10 a.m. Central, 8 a.m. Pacific
Why call? To gain understand the meaning of the results of the drug trials and to ask questions
The call will be recorded and will be made available later in the day for those who miss the live call. You may call the replay three or more hours after the call by calling the number below and using the Conference ID: 52075135.
| | |
| Encore dial-in #: Toll-free (855) 859-2056 or (404) 537-3406
***In addition to the toll-free number listed above, participants can also dial (800) 585-8367 to access Encore*** the replay information will also be posted at http://www.coalitionforpf.org/category/news-events/pf-news/ within 3 or more hours of the call. |
About Pulmonary Fibrosis (PF)
Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis — and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 200,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).
About the CPF
The CPF is a 501C(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF’s nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 28,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541
.
 | |
No comments:
Post a Comment